Verona Pharma price target raised to $85 from $75 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $85 from $75 and keeps a Buy rating on the shares. The firm says the company’s sales continue to soundly beat its revenue forecasts. The commercialization of Verona’s sole marketed product, Ohtuvayre, “continues at a torrid pace,” the analyst tells investors in a research note.